Clinical trial data can be remarkably (and unnecessarily) difficult to read. Companies spin, short-sellers hawk, and everyone else is left swimming through the muck. But there is an art to reading scientific results — and you can learn it.
Subscribe to STAT Plus to join STAT national biotech columnist Adam Feuerstein and STAT senior science writer Sharon Begley for a special subscriber-only webinar on interpreting clinical trial data. They will share their recommendations on what to look for — and what not to fall for — when trying to make sense of the data. They’ll also walk through some case studies to help you prepare for the next big readout.